

09/ 724,778

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 DEC 08 INPADOC: Legal Status data reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded
NEWS 17 DEC 08 CABA reloaded with left truncation
NEWS 18 DEC 08 IMS file names changed
NEWS 19 DEC 09 Experimental property data collected by CAS now available
in REGISTRY
NEWS 20 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS 21 DEC 17 DGENE: Two new display fields added
NEWS 22 DEC 18 BIOTECHNO no longer updated
NEWS 23 DEC 19 CROPU no longer updated; subscriber discount no longer
available

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:07:05 ON 19 DEC 2003

09/ 724,778

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:07:12 ON 19 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 DEC 2003 HIGHEST RN 627518-95-0

DICTIONARY FILE UPDATES: 18 DEC 2003 HIGHEST RN 627518-95-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading 09724778.str


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

09/ 724,778



G1 O, N, Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 16:07:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 541 TO ITERATE

100.0% PROCESSED 541 ITERATIONS 148 ANSWERS
SEARCH TIME: 00.00.01

L2 148 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY TOTAL
SESSION

FILE 'CAPLUS' ENTERED AT 16:08:07 ON 19 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

09/ 724,778

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Dec 2003 VOL 139 ISS 26
FILE LAST UPDATED: 18 Dec 2003 (20031218/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12

L3 4 L2

=> d l3 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:678784 CAPLUS

DOCUMENT NUMBER: 139:214481

TITLE: Syntheses of enantiomerically pure quinazolinones
INVENTOR(S): Bergnes, Gustav; Ha, Edward; Yiannikourous, George;
Kalaritis, Panos; Yonce, Brandon E.; Welday, Kurt
Alan, Jr.

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA; SmithKline Beecham Corp.
SOURCE: PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070701	A2	20030828	WO 2003-US4713	20030214
WO 2003070701	A3	20031016		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-357244P P 20020215
US 2002-380746P P 20020514


OTHER SOURCE(S): MARPAT 139:214481

GI



- AB The present invention provides intermediates, synthetic methods and novel quinazolinone (shown as I; e.g. (R)-N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide) compns. of matter, which are inhibitors of the mitotic kinesin KSP (no data) and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation (no data); only the compds., compns. of matter and synthetic methods are claimed. The method comprises contacting HO₂CCH(R₂)NHX (R₂ = oxaalkyl or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; X = H, protecting group (e.g. Boc, CBZ, phthalide, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl); e.g. valine) with iso-Bu chloroformate followed by contacting the resulting product with (un)substituted 2-aminobenzoic acids to give I. Eight example prepns. of I are included. For example, (S)-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester was prepd. starting from N-Boc-L-valine and involving intermediates 2-[[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino]-4-chlorobenzoic acid, (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester, (S)-[1-[[2-benzylcarbamoyl-5-chlorophenyl]imino]methyl]-2-methylpropyl]carbamic acid tert-Bu ester (in mixt. with the final product). In the key step, to 2-[[2-[(tert-butoxycarbonyl)amino]-L-3-methylbutyryl]amino]-4-chlorobenzoic acid was added 13.2 mL (0.1 mol) of iso-Bu chloroformate over 15 min (internal temp. 5.degree.) followed by the addn. of 11.1 mL (0.1 mol) of anhyd. N-methylmorpholine over 15 min at 0.degree.; the mixt. was stirred for an addnl. hour at 0.degree. to give (S)-[1-(7-chloro-4-oxo-4H-benzo[d][1,3]oxazin-2-yl)-2-methylpropyl]carbamic acid tert-Bu ester. For I: R₁ is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R₃ is H, oxaalkyl, R₉O-, R₉NH- or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, or oxaalkylaryl; R₄ is H or (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl; R₅, R₆, R₇ and R₈ = H, hydroxy, (un)substituted alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, amino, alkylamino, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl or heteroaryl; and R₉ is (un)substituted alkyl, aryl, alkylaryl, heteroaryl, or alkylheteroaryl. The compns. of matter comprise I and detectable amts. of .gtoreq.1 unreacted starting materials and/or a cyclo-dehydration reagent; they are claimed, presumably because it is important to monitor the purity of pharmaceutical compds. for the presence of such materials, which presence comprises a way of detecting use of a process of the invention.
- IT 336113-53-2P, (R)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
 587881-28-5P, (R)-[3-[[1-(3-Benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl](4-methylbenzoyl)amino]propyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (syntheses of enantiomerically pure quinazolinones)
- RN 336113-53-2 CAPLUS
- CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 587881-28-5 CAPLUS

CN Carbamic acid, [3-[[[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl](4-methylbenzoyl)amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 336113-54-3P, (S)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide
 587881-21-8P, (R)-N-(3-Aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide mesylate
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (syntheses of enantiomerically pure quinazolinones)

RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09/ 724,778




RN 587881-21-8 CAPLUS
CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 336113-53-2
CMF C30 H33 Cl N4 O2

Absolute stereochemistry.



CM 2



CRN 75-75-2
CMF C H4 O3 S



09/ 724,778

ACCESSION NUMBER: 2003:417728 CAPLUS
DOCUMENT NUMBER: 139:6884
TITLE: Process for the racemization of chiral quinazolinones
INVENTOR(S): Yao, Bing; Smith, Whitney W.; Bergnes, Gustave;
Morgans, David, Jr.
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043995	A1	20030530	WO 2002-US37410	20021120
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003166933	A1	20030904	US 2002-300967	20021120
PRIORITY APPLN. INFO.:			US 2001-332148P	P 20011120
OTHER SOURCE(S):		MARPAT 139:6884		
GI				



AB Racemates were obtained from one of the enantiomers, or an enantiomerically enriched mixt., of an optically active quinazolinone deriv. I [wherein R1 = H or (un)substituted alkyl, (hetero)aryl, or (hetero)aralkyl; R2 = oxaalkyl or (un)substituted alkyl, (hetero)aryl, or (hetero)aralkyl; R5-R8 = independently H, (fluoro)alkyl, alkoxy, halo, NO2, dialkylamino, alkylsulfonyl, alkylsulfamido(alkyl), sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, or (hetero)aryl] by reaction of the compd. with an alkali alkoxide of a primary alc. and isolation of the racemate. For example, treatment of (S)-II with NaOEt (21% by wt. soln. in denatured alc. contg. 5% toluene) in abs. EtOH and heating at reflux for 36 h, followed by crystn. gave (.+-.)-II in a 1:1.1 mixt. of (R)- and (S)-isomers. The invention also provides for the subsequent resoln. of the racemate and use of the other enantiomer in the synthesis of pharmacol. active therapeutic agents. Thus, an efficient method of converting an inactive or undesirable enantiomer into the other usable, desirable enantiomer is disclosed.


09/ 724,778

IT 533926-44-2P

RL: IMF (Industrial manufacture); PREP (Preparation)
(racemate; prepn. and racemization of chiral quinazolinones)

RN 533926-44-2 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




IT 533926-43-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(undesirable enantiomer; prepn. and racemization of chiral quinazolinones)

RN 533926-43-1 CAPLUS

CN Benzamide, 4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:935583 CAPLUS

DOCUMENT NUMBER: 136:53759

TITLE: Preparation of N-acylquinazolinonealkylamines as KSP kinesin inhibitors

INVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustav; Feng, Bainian; Smith, Whitney W.; Chabala, John C.; Morgans, David J., Jr.

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA


SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

09/ 724,778

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098278	A1	20011227	WO 2001-US13901	20010427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6545004	B1	20030408	US 2000-699047	20001024
JP 2003048881	A2	20030221	JP 2002-156766	20001026
US 6562831	B1	20030513	US 2000-724644	20001128
US 6630479	B1	20031007	US 2000-724713	20001128
EP 1296959	A1	20030402	EP 2001-932769	20010427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011898	A	20030513	BR 2001-11898	20010427
NO 2002006172	A	20030220	NO 2002-6172	20021220
PRIORITY APPLN. INFO.:				
			US 2000-213104P	P 20000621
			US 2000-699047	A 20001024
			US 1999-198253P	P 19991027
			JP 2001-533122	A3 20001026
			WO 2001-US13901	W 20010427
OTHER SOURCE(S): MARPAT 136:53759				
GI				



AB R1CR2R2'NRR4 [I; R = H, COR3, SO2R3', CH2R3''; R1 = (un)substituted 3,4-dihydro-4-oxoquinazolin-2-yl; R2,R2' = H, (oxa)alkyl, (hetero)aryl, etc.; R3 = H, alkyl, alkoxy, (hetero)aryl, etc.; R3',R4 = H, alkyl, (hetero)aryl, etc.; R3'' = alkyl, (hetero)aryl, etc.] were prep'd. Thus, 2-(H2N)C6H4CO2H was amidated by PrCOCl and the cyclized product cyclocondensed with PhCH2NH2 to give, after bromination, quinazolinone II (R = Br) which was converted in 2 steps to II [R = N(COC6H4F-4)CH2CH2NMe2]. Data for biol. activity of I were given.

IT 336113-53-2P 336113-54-3P 336113-69-0P
 336113-70-3P 336113-71-4P 336113-72-5P
 336113-73-6P 336115-02-7P 336115-04-9P
 336115-06-1P 336115-09-4P 336115-11-8P
 336115-13-0P 336115-15-2P 336115-17-4P
 336115-19-6P 336115-22-1P 336115-24-3P
 336115-26-5P 336115-28-7P 336115-30-1P
 336115-32-3P 336115-34-5P 336115-36-7P
 336115-38-9P 336115-42-5P 336115-44-7P

336115-46-9P 336115-48-1P 336115-50-5P
 336115-52-7P 336115-54-9P 336115-56-1P
 336115-58-3P 336115-60-7P 336115-62-9P
 336115-64-1P 336115-66-3P 336115-68-5P
 336115-70-9P 336115-72-1P 336115-74-3P
 336115-76-5P 336115-78-7P 336115-80-1P
 336115-82-3P 336115-84-5P 336115-86-7P
 336115-88-9P 336115-95-8P 336115-99-2P
 336116-01-9P 336116-03-1P 336116-05-3P
 336116-07-5P 336116-09-7P 336116-11-1P
 336116-13-3P 336116-15-5P 336116-19-9P
 336116-21-3P 336116-23-5P 336116-25-7P
 336116-29-1P 336116-31-5P 336116-35-9P
 336116-37-1P 336116-39-3P 336116-41-7P
 336116-43-9P 336116-45-1P 336116-47-3P
 336116-51-9P 336116-53-1P 336116-57-5P
 336116-61-1P 336116-67-7P 336116-71-3P
 336116-73-5P 336116-75-7P 336116-77-9P
 336116-79-1P 336116-81-5P 336116-83-7P
 336116-85-9P 336116-87-1P 336116-89-3P
 336116-91-7P 336116-95-1P 336116-97-3P
 336116-99-5P 336117-01-2P 336117-03-4P
 336117-05-6P 336117-07-8P 336117-09-0P
 336117-13-6P 336117-15-8P 336117-19-2P
 336117-21-6P 336117-24-9P 336117-26-1P
 336117-28-3P 336117-34-1P 336117-36-3P
 336117-38-5P 336117-42-1P 336117-44-3P
 336117-46-5P 336117-48-7P 336117-50-1P
 336117-52-3P 336117-56-7P 336117-67-0P
 336117-71-6P 336117-82-9P 336117-84-1P
 336117-86-3P 336117-90-9P 336117-92-1P
 336118-12-8P 336118-27-5P 336118-36-6P
 336118-39-9P 336118-43-5P 336118-45-7P
 336118-49-1P 336118-53-7P 336118-61-7P
 336118-66-2P 336119-15-4P 336119-17-6P
 336119-19-8P 336119-23-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-acylquinazolinonealkylamines as KSP kinesin inhibitors)

RN 336113-53-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-
 (phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




09/ 724,778

RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-69-0 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-70-3 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 724,778



RN 336113-71-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336113-72-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-73-6 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 724,778



RN 336115-02-7 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-[(1-methylethyl)amino]propyl]- (9CI)
 (CA INDEX NAME)




RN 336115-04-9 CAPLUS
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(4-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-06-1 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778



RN 336115-09-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(3-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-11-8 CAPLUS

CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336115-13-0 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336115-15-2 CAPLUS

CN Benzamide, N-(3-azetidinylmethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-17-4 CAPLUS

CN Benzamide, N-(2-aminoethyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-19-6 CAPLUS


CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336115-22-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-24-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(methylamino)propyl]- (9CI) (CA INDEX NAME)



RN 336115-26-5 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-28-7 CAPLUS

CN Benzamide, N-[(2R)-2-azetidinylmethyl]-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

09/ 724,778




RN 336115-30-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336115-32-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylthio)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-34-5 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)



09/ 724,778

RN 336115-36-7 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336115-38-9 CAPLUS


CN Benzamide, 4-bromo-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 336115-42-5 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-(2-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 336115-44-7 CAPLUS

CN Benzamide, N-(4-aminobutyl)-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


09/ 724,778



RN 336115-46-9 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(3-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-48-1 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-50-5 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336115-52-7 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1H-imidazol-4-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-54-9 CAPLUS
CN Benzamide, N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-(3-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336115-56-1 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)


09/ 724,778



RN 336115-58-3 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-60-7 CAPLUS
CN Benzamide, 4-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-62-9 CAPLUS
CN Benzamide, N-(4-aminobutyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)


09/ 724,778




RN 336115-64-1 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-(2-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 336115-66-3 CAPLUS
 CN Benzamide, N-[3-(1-azetidinyl)propyl]-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-68-5 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-70-9 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 336115-72-1 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 336115-74-3 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]butyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336115-76-5 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 336115-78-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336115-80-1 CAPLUS


CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 336115-82-3 CAPLUS
 CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylthio)propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336115-84-5 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-(1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336115-86-7 CAPLUS
 CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-phenylethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 724,778



RN 336115-88-9 CAPLUS
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[(1-ethyl-2-pyrrolidiny)methyl]- (9CI) (CA INDEX NAME)




RN 336115-95-8 CAPLUS
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)-2,2-dimethylpropyl]- (9CI) (CA INDEX NAME)




RN 336115-99-2 CAPLUS
 CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)


09/ 724,778




RN 336116-01-9 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(2-methyl-1-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 336116-03-1 CAPLUS
CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-05-3 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-07-5 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(dimethylamino)propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-09-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(diethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 336116-11-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336116-13-3 CAPLUS

CN Carbamic acid, [5-[(3-aminopropyl)(4-methylbenzoyl)amino]-5-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 336116-15-5 CAPLUS


CN Benzamide, N-[2-(2-aminoethoxy)ethyl]-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-19-9 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-cyclohexylethyl]-4-methyl- (9CI) (CA INDEX NAME)


09/ 724,778



RN 336116-21-3 CAPLUS
CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-23-5 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(3-hydroxypropyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-25-7 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336116-29-1 CAPLUS

CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336116-31-5 CAPLUS


CN Benzamide, 4-bromo-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336116-35-9 CAPLUS


CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336116-37-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-39-3 CAPLUS

CN Benzamide, N-[5-amino-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]pentyl]-N-(3-aminopropyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 336116-41-7 CAPLUS


CN Benzamide, N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336116-43-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(3-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-45-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[6,7-difluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-47-3 CAPLUS

CN .beta.-Alanine, N-(4-bromobenzoyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336116-51-9 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-53-1 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 336116-57-5 CAPLUS
 CN Benzamide, 3-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-61-1 CAPLUS
 CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 336116-67-7 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 336116-71-3 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-methyl-N-[3-(1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336116-73-5 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


09/ 724,778




RN 336116-75-7 CAPLUS
CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 336116-77-9 CAPLUS
CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 336116-79-1 CAPLUS
CN Benzamide, 4-bromo-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336116-81-5 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(phenylmethoxy)ethyl]-4-methyl- (9CI)
(CA INDEX NAME)




RN 336116-83-7 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-3-(methylsulfinyl)propyl]-4-methyl- (9CI)
(CA INDEX NAME)




RN 336116-85-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-87-1 CAPLUS


CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 336116-89-3 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 336116-91-7 CAPLUS
 CN Benzamide, 3,4-dichloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-95-1 CAPLUS
 CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336116-97-3 CAPLUS

CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 336116-99-5 CAPLUS

CN .beta.-Alanine, N-(4-bromobenzoyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336117-01-2 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-3-[(4-methoxyphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336117-03-4 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(methylsulfinyl)ethyl]-4-methyl- (9CI)
(CA INDEX NAME)

09/ 724,778




RN 336117-05-6 CAPLUS

CN Benzamide, N-[[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]-4-methyl-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 336117-07-8 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 336117-09-0 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-hydroxyethyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336117-13-6 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 336117-15-8 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 336117-19-2 CAPLUS

CN Benzamide, 4-bromo-N-[[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-21-6 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)- (9CI)


09/ 724,778

(CA INDEX NAME)




RN 336117-24-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3-[(2-chlorophenyl)methyl]-3,4-dihydro-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-26-1 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-28-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[1-cyclohexyl-4-(diethylamino)butyl]- (9CI) (CA INDEX NAME)




RN 336117-34-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(2-hydroxyethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 336117-36-3 CAPLUS


CN Benzamide, N-[2-(dimethylamino)ethyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336117-38-5 CAPLUS


CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336117-42-1 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 336117-44-3 CAPLUS


CN Benzamide, N-[2-[bis(1-methylethyl)amino]ethyl]-4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336117-46-5 CAPLUS


CN Benzamide, N-(2-aminoethyl)-N-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]methyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336117-48-7 CAPLUS

CN Benzamide, N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336117-50-1 CAPLUS


CN Benzamide, N-[3-(dimethylamino)propyl]-4-fluoro-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)




RN 336117-52-3 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[4-(diethylamino)-1-methylbutyl]- (9CI) (CA INDEX NAME)


09/ 724,778



RN 336117-56-7 CAPLUS
CN Benzamide, N-[1-[5-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 336117-67-0 CAPLUS
CN Benzamide, 4-bromo-N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336117-71-6 CAPLUS
CN Benzamide, 3-chloro-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336117-82-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 336117-84-1 CAPLUS

CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 336117-86-3 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336117-90-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 336117-92-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)



RN 336118-12-8 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



09/ 724,778


RN 336118-27-5 CAPLUS

CN Benzamide, 4-cyano-N-[3-(dimethylamino)propyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)



RN 336118-36-6 CAPLUS

CN Benzamide, 4-cyano-N-[2-(dimethylamino)ethyl]-N-[1-[7-fluoro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)





RN 336118-39-9 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 336118-43-5 CAPLUS

CN Benzamide, N-[1-[8-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336118-45-7 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-3-[(2-methylphenyl)methyl]-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336118-49-1 CAPLUS


CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]propyl]-4-methyl- (9CI) (CA INDEX NAME)

09/ 724,778




RN 336118-53-7 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336118-61-7 CAPLUS

CN Carbamic acid, [3-[(4-bromobenzoyl)[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 336118-66-2 CAPLUS


CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 336119-15-4 CAPLUS
 CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-4-fluoro-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 336119-17-6 CAPLUS
 CN .beta.-Alanine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 336119-19-8 CAPLUS
 CN Glycine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 336119-23-4 CAPLUS
 CN Benzoic acid, 4-[[[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl][2-(dimethylamino)ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2001:319882 CAPLUS
 DOCUMENT NUMBER: 134:326543
 TITLE: Methods and compositions utilizing quinazolinones as KSP kinesin modulators
 INVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustave; Feng, Bainian; Smith, Whitney W.; Chabala, John C.
 PATENT ASSIGNEE(S): Cytokinetics, Inc., USA
 SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030768	A1	20010503	WO 2000-US29585	20001026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000015110	A	20020702	BR 2000-15110	20001026
EP 1226129	A1	20020731	EP 2000-976656	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003048881	A2	20030221	JP 2002-156766	20001026
JP 2003512461	T2	20030402	JP 2001-533122	20001026
US 6562831	B1	20030513	US 2000-724644	20001128
US 6630479	B1	20031007	US 2000-724713	20001128
ZA 2002002930	A	20021028	ZA 2002-2930	20020415
NO 2002001907	A	20020607	NO 2002-1907	20020423
PRIORITY APPLN. INFO.:			US 1999-198253P	P 19991027
			US 2000-213104P	P 20000621
			US 2000-699047	A1 20001024
			JP 2001-533122	A3 20001026
			WO 2000-US29585	W 20001026

OTHER SOURCE(S): MARPAT 134:326543
GI



AB Quinazolinones (I) [wherein R1 = H, alkyl, (hetero)aryl, or (un)substituted alkyl(hetero)aryl; R2 and R2a = independently H or (un)substituted (oxa)alkyl, (hetero)aryl, or alkyl(hetero)aryl; Y = NR4COR3, NR4SO2R3a, NR4CH2R3b, or NHR4; R3 = H, oxaalkyl, or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, oxaalkylaryl, ether, or amino; R3a = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or amino; R3b = (un)substituted alkyl, (hetero)aryl, or alkyl(hetero)aryl; R4 = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or alkylene; R5-R8 = independently H, (fluoro)alkyl, alkoxy, halo, NO2, dialkylamino, alkylsulfonyl, alkylsulfonamido(alkyl or aryl), alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, or (hetero)aryl] were prepd. by conventional and solid phase combinatorial synthetic methods as KSP kinesin inhibitors for treatment of cellular proliferative diseases. For example, II was synthesized in a 6-step sequence involving (1) amidation of anthranilic acid with butyryl chloride (65%), (2) cyclization to give 2-propyl-3,1-[4H]benzoxazin-4-one (62%), (3) treatment with PhCH2NH2 to give 2-propyl-3-benzylquinazolin-4-one (67%), bromination (92%), addn. of N,N-dimethylethylenediamine (55%), and (6) amidation with p-fluorobenzoyl chloride (65%). I are useful for treating cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, and inflammation (no data). Methods of screening for compds. that will bind to a KSP kinesin or are modulators of KSP kinesin activity are also disclosed.


IT 336115-13-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of quinazolinone KSP kinesin modulators via conventional and

solid phase combinatorial synthetic methods)

RN 336115-13-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)



IT 336113-53-2P 336113-54-3P 336113-69-0P
 336113-70-3P 336113-71-4P 336113-72-5P
 336113-73-6P 336115-02-7P 336115-04-9P
 336115-06-1P 336115-09-4P 336115-11-8P
 336115-15-2P 336115-17-4P 336115-19-6P
 336115-22-1P 336115-24-3P 336115-26-5P
 336115-28-7P 336115-30-1P 336115-32-3P
 336115-34-5P 336115-36-7P 336115-38-9P
 336115-42-5P 336115-44-7P 336115-46-9P
 336115-48-1P 336115-50-5P 336115-52-7P
 336115-54-9P 336115-56-1P 336115-58-3P
 336115-60-7P 336115-62-9P 336115-64-1P
 336115-66-3P 336115-68-5P 336115-70-9P
 336115-72-1P 336115-74-3P 336115-76-5P
 336115-78-7P 336115-80-1P 336115-82-3P
 336115-84-5P 336115-86-7P 336115-88-9P
 336115-95-8P 336115-99-2P 336116-01-9P
 336116-03-1P 336116-05-3P 336116-07-5P
 336116-09-7P 336116-11-1P 336116-13-3P
 336116-15-5P 336116-19-9P 336116-21-3P
 336116-23-5P 336116-25-7P 336116-29-1P
 336116-31-5P 336116-35-9P 336116-37-1P
 336116-39-3P 336116-41-7P 336116-43-9P
 336116-45-1P 336116-47-3P 336116-51-9P
 336116-53-1P 336116-57-5P 336116-61-1P
 336116-67-7P 336116-71-3P 336116-73-5P
 336116-75-7P 336116-77-9P 336116-79-1P
 336116-81-5P 336116-83-7P 336116-85-9P
 336116-87-1P 336116-89-3P 336116-91-7P
 336116-95-1P 336116-97-3P 336116-99-5P
 336117-01-2P 336117-03-4P 336117-05-6P
 336117-07-8P 336117-09-0P 336117-13-6P
 336117-15-8P 336117-19-2P 336117-21-6P
 336117-24-9P 336117-26-1P 336117-28-3P
 336117-34-1P 336117-36-3P 336117-38-5P
 336117-42-1P 336117-44-3P 336117-46-5P
 336117-48-7P 336117-50-1P 336117-52-3P
 336117-56-7P 336117-67-0P 336117-71-6P
 336117-82-9P 336117-84-1P 336117-86-3P
 336117-90-9P 336117-92-1P 336118-12-8P
 336118-27-5P 336118-36-6P 336118-39-9P
 336118-43-5P 336118-45-7P 336118-49-1P
 336118-53-7P 336118-61-7P 336118-66-2P
 336119-15-4P 336119-17-6P 336119-19-8P
 336119-23-4P

09/ 724,778


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336113-53-2 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 336113-54-3 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 336113-69-0 CAPLUS

CN Benzamide, N-(2-aminoethyl)-4-bromo-N-[(1S)-1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 724,778




RN 336119-17-6 CAPLUS

CN .beta.-Alanine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 336119-19-8 CAPLUS


CN Glycine, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-(4-methylbenzoyl)- (9CI) (CA INDEX NAME)



RN 336119-23-4 CAPLUS

CN Benzoic acid, 4-[[[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl][2-(dimethylamino)ethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

09/ 724,778



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:07:05 ON 19 DEC 2003)

FILE 'REGISTRY' ENTERED AT 16:07:12 ON 19 DEC 2003

L1 STRUCTURE UPLOADED

L2 148 S L1 FUL

FILE 'CAPLUS' ENTERED AT 16:08:07 ON 19 DEC 2003

L3 4 S L2

=> log y